ImmunityBio Expands ANKTIVA Access Across Europe Through New Distribution Partnership and Irish Subsidiary
Accord Healthcare Partnership Brings ANKTIVA to 33 Countries
ImmunityBio took a major strategic leap this week, announcing a distribution partnership with Accord Healthcare to make ANKTIVA® (nogapendekin alfa inbakicept) available to eligible patients across the European Union and beyond. With a commercial team exceeding 100 professionals, Accord will drive ANKTIVA commercialization in 30+ countries, aiming to reach patients diagnosed with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ—including those with or without papillary tumors.
Irish Subsidiary Supports Pan-European Market Entry
To streamline operations and distribution, ImmunityBio has established a new subsidiary in Dublin. This launch strengthens the company's European infrastructure and positions it to facilitate faster patient access and market scale-up efforts throughout the continent.
Regulatory Footprint and Market Opportunity: 33 Country Approvals
ANKTIVA, now authorized for use in 33 jurisdictions—including the United States, United Kingdom, Saudi Arabia, and across the entire European Economic Area—addresses a critical need. Roughly 157,000 people are diagnosed annually with NMIBC in the EU and UK, with 10%–20% presenting with carcinoma in situ, making timely access and effective therapies crucial for outcomes.
| Region | Regulatory Authority | Approval Date | Countries Covered |
|---|---|---|---|
| United States | FDA | Apr 2024 | 1 |
| United Kingdom | MHRA | Jul 2025 | 1 |
| Saudi Arabia | SFDA | Jan 2026 | 1 |
| European Union & EEA | European Commission | Feb 2026 | 30 (27 EU + Iceland, Liechtenstein, Norway) |
ANKTIVA's Clinical Lead: High Response and Durability
A standout from clinical trials, ANKTIVA combined with BCG delivers a 71% complete response rate for BCG-unresponsive NMIBC carcinoma in situ patients. This robust efficacy profile has been central to gaining multiple regulatory approvals and underpins ImmunityBio's mission to broaden access in regions where the disease remains a significant burden.
Product Overview: A Next-Generation Immune Booster
ANKTIVA is a first-in-class interleukin-15 receptor agonist, activating natural killer (NK) cells, CD4+ T cells, and CD8+ T cells—which are crucial for sustained anti-tumor immunity. Enhanced pharmacokinetics and longer lymphoid tissue persistence differentiate it from native IL-15, helping restore immune activity and fight tumor escape mechanisms that are common in bladder cancer.
Market Implications: Leadership in Bladder Cancer Therapy
By leveraging Accord's formidable market reach and launching an Irish subsidiary to anchor European operations, ImmunityBio positions ANKTIVA as a central therapy for bladder cancer in Europe. Ongoing regulatory activities—including a submission to the U.S. FDA for an expanded NMIBC indication and an imminent readout from a randomized BCG-naïve trial—hint at continued momentum and growth for the company.
Key Safety and Administration Highlights
- Indication: Combined with BCG for adult patients with BCG-unresponsive NMIBC with carcinoma in situ (with/without papillary tumours).
- Administration: Intravesical only, mixed with BCG—never subcutaneous, intravenous, or intramuscular.
- Risks: Consider potential for severe BCG infections. Delay in cystectomy increases risk of progression to muscle-invasive or metastatic cancer.
- Pregnancy: Not recommended for women who are pregnant or not using effective contraception.
What to Watch Going Forward
The partnership with Accord and the recent regulatory wins suggest ImmunityBio is set for meaningful impact in the European cancer therapy landscape. With a clinical response rate that supports label expansion and broadening patient access, the next major catalysts will likely stem from ongoing clinical trial results and the pace of actual uptake across the newly accessible markets.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI